Although, currently only few data are available to document the adverse consequences generated by the integration between the ET-1R axis and the YAP and TAZ signaling in the tumor ecosystem (Fig. 1), the preclinical findings [87–89, 95, 97] raise the possibility that ET-1R blockade could be effective against ET-1R/YAP/TAZ-driven tumors, ameliorating the outcomes of the patients. The gene discussed is YAP1; the disease is neoplasm.